TP53 and breast cancer: Comparisons conducted in this study revealed a higher prevalence of the Her2 molecular subtypes, higher prevalence of TP53 mutations in ER+ disease and higher overall immune signatures in Asian breast cancer, all of which could impact clinical outcomes.